Navigation Links
Hospira Launches Biologics 'Clock' and Web Resource to Raise Awareness of Potential Biogenerics' Impact
Date:5/5/2009

- Clock Shows $1,331 Per Second In Biologic Drug Sales -

LAKE FOREST, Ill., May 5 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today launched a clock tracking real-time U.S. prescription sales of costly biologic drugs as part of an informational Web resource highlighting the potential impact of biogenerics - generic versions of biologics - on the U.S. healthcare system. Although biogenerics are widely available in Europe and other parts of the world today, there is currently no legislative pathway allowing the U.S. Food and Drug Administration (FDA) to approve these safe, cost-effective alternatives for Americans.

"As the first U.S. company to launch a biogeneric medicine in Europe, Hospira brings unique expertise to the growing effort to create a regulatory pathway for these life-saving and life-enhancing drugs in the United States," said Christopher B. Begley, chairman and chief executive officer, Hospira. "We enthusiastically support legislation in Congress to make high-quality, safe and more affordable biogenerics available in this country."

The clock, available at www.hospira.com, gives a year-to-date approximation of biologic drug sales. It is continually updated so visitors can watch the numbers tick away, at a rate of $1,331 per second, or an estimated $42 billion a year.(1) The site also provides links to a study showing the potential billions of dollars in savings associated with biogenerics and encourages visitors to make their voices heard in Washington, D.C., as Congress considers legislation to bring biogenerics to market.

In Europe, the introduction of biogenerics has led to price savings of 20 to 30 percent in some markets.(2) Hospira's biogeneric, Retacrit(R) (epoetin zeta), is a treatment for anemia associated with chronic kidney failure and chemotherapy-induced anemia, and is available in 15 European countries today. Since launch in early 2008, Retacrit has obtained a 30 percent share of the biogenerics market for its drug class.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.

(1) Hospira research based on IMS Health, news release, June 17, 2008; "IMS Health Reports Global Biotech Sales Grew 12.5 Percent in 2007, Exceeding $75 Billion." U.S. sales accounted for 56 percent of world sales in 2007, according to IMS, which equates to an estimated $42 billion in U.S. sales. The Congressional Budget Office (CBO) says spending on biologics has grown in the United States, "exceeding $40 billion" in 2007 (Budget Options; Volume 1: Health Care, December 2008).

(2) Hospira internal data.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira Reports First-Quarter 2009 Results
2. Hospira to Host Conference Call for First-Quarter 2009 Results
3. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
4. Hospira Expands Board of Directors
5. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
6. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
7. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
8. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
9. Hospira Names Ken Meyers to Lead Human Resources
10. Hospira Reports Third-Quarter 2008 Results
11. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... Digital Scientists, a software innovation lab specializing in web design and ... Carolina location. The lab has set up shop at the renowned NEXT Innovation ... Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ CEO, ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... planning, and related services to families and business owners across eastern Michigan, is ... feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry ...
(Date:3/24/2017)... ... 2017 , ... On June 9, 2017, Cassie Springer Ayeni ... in Chicago, Illinois. She will present on: , Filing Benefit Claims—Responding to ... involve claims for long-term disability benefits. This session will address the first ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks at ... his life to the fullest, as God intended. “The Adventures of Joey, The Dog ... and grandmother pursuing her passion for writing, especially about truth and human behavior. , ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Idiopathic ... ... strong with a total of 97 drug candidates. Pharma giant such as ... in the development of the IPF therapeutics. The IPF pipeline comprised of ... are in Phase II stage, 12 are in Phase I stage, 39 ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Supplies - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:3/24/2017)... 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today disclosed ... Term Sheet (the "Definitive Financing") it entered into ... Company,s stockholders, who are referred to in the ... 8-K filed with the Securities and Exchange Commission. ...
Breaking Medicine Technology: